Comirnaty COVID-19 Vaccine Production Increased 50%

New York-based Pfizer's Chief Executive Officer Albert Bourla announced the drugmaker and its German partner BioNTech SE would be able to deliver 200 million Comirnaty vaccine doses to the U.S. well before an earlier July 31, 2021, deadline due to a change in the vaccine’s label that allows an additional dose to be extracted from each vial, for a total of six doses, Bloomberg reported on January 26, 2021.

In total, Pfizer and BioNTech plan to produce 2 billion Comirnaty vaccine doses of 0.3 mL each in 2021, a 50% increase from 2020 estimates.

The Comirnaty (BNT162b2) (Tozinameran) mRNA vaccine was issued the first U.S. Food and Drug Administration (FDA) emergency use authorization on December 11, 2020. However, the experimental Comirnaty COVID-19 vaccine has not been Approved or Licensed by the U.S. FDA.